Pollution in China

A 2015 report by Sum Of Us reveals that the largest pharmaceutical corporations are complicit in fuelling one of the most serious public health crises facing society today. Pharmaceutical companies, including this one, are sourcing active pharmaceutical ingredients (APIs) from companies in China which are responsible for massive environmental pollution from its antibiotic factories. Teva has links with at least three of the Chinese companies identified in the report, all of which have been in the Chinese media spotlight for various offences including improper waste management and the release of noxious chemicals.

Source: Changing Markets (2015)

34.2% in Newsweek Green Ranking 2017

This company received a score of 34.2/100 in the Newsweek Green Ranking 2017, which ranks the world's largest publicly traded companies on eight indicators covering energy, greenhouse gases, water, waste, fines and penalties, linking executive pay to sustainability targets, board-level committee oversight of environmental issues and third-party audits. Ranking methodology by Corporate Knights and HIP Investor.

Source: Newsweek (2017)

$519m bribery settlement

In 2016 this company agreed to pay more than $519 million to settle US criminal and civil allegations that the company bribed officials in Mexico, Russia and Ukraine to gain business for its medications. [Listed under Information due to age of court finding]

Source: news article (2016)

$1.2b antitrust settlement

In 2015 this company agreed to pay US$1.2 billion to settle charges that one of its subsidiaries illegally blocked the launch of low-cost generic versions of the blockbuster sleeping pill Provigil. The settlement stems from charges brought in 2008 against Cephalon Inc, which was acquired by Teva in 2012.

Source: news article (2015)

Involvement with Israel

The independent research centre Who Profits has identified this company as complicit in Israel's ongoing occupation of Palestinian and Syrian land. "As a dominant part of the Israeli pharmaceutical industry, Teva enjoys the advantages generated by the Israeli occupation of Palestinian lands allowing the company to exploit the Palestinian market. 'Quality and Security reasons' in conjunction with economic and political justifications create a Palestinian captive market for Israeli and multinational companies."

Source: Who Profits (2024)

Product carbon footprint label

This company has products that are certified by the Carbon Trust, signifying that the carbon footprint of selected products has been measured, managed and reduced. A life cycle product carbon footprint is determined by calculating the total greenhouse gas emissions generated by a product, from extraction of raw-materials, to end-of-life.

Source: Carbon Trust (2021)

Climate action commitments

As listed on the We Mean Business website, this company has committed to the following climate action initiatives: adopt a science-based emissions reduction target.

Source: We Mean Business (2021)

Gender equality

This company appears on the 2023 Bloomberg Gender-Equality Index, signifying a commitment to supporting gender equality through policy development, representation, and transparency.

Source: Bloomberg (2023)

Responsibility claims

This company has Responsibility claims on its website.

Source: company website (2018)

AMR Industry Alliance member

This company is a member of the AMR Industry Alliance, a coalition of biotech, diagnostics, generics and research-based pharmaceutical companies set up to provide sustainable solutions to curb antimicrobial resistance (AMR). AMR is an increasingly significant threat to global public health which puts at risk the effective prevention and treatment of a wide range of infections.

Source: AMR Industry Alliance (2021)

60% in AMR Benchmark

The 2021 Antimicrobial Resistance (AMR) Benchmark ranks 17 large pharmaceutical companies on their efforts keep medicines and vaccines available, despite the rise of drug resistance. This company received a score of 60%.

Source: Access to Medicine Foundation (2021)

54/100 S&P Global ESG Score

This company received an S&P Global ESG Score of 54/100 in the Pharmaceuticals category of the S&P Global Corporate Sustainability Assessment, an annual evaluation of companies' sustainability practices (last updated 16 Dec 2022). The rankings are based on an analysis of corporate economic, environmental and social performance, assessing issues such as corporate governance, risk management, environmental reporting, climate strategy, human rights and labour practices.

Source: S&P Global (2022)

21.7% in Nature Benchmark

The Nature Benchmark ranks 816 companies across 20 industries on their efforts to protect our environment and its biodiversity. Companies were assessed in three phases between 2022 and 2024 using three measurement areas: governance and strategy; social inclusion and community impact; and ecosystems and biodiversity. This company was assessed in 2022 and is ranked #218/816, with a total score of 21.7/100.

Source: World Benchmarking Alliance (2022)